Nexstim Oyj: Nexstim Receives an NBT System Order from a New Therapy Customer in Finland
Therapy Customer in Finland
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that it has received a new NBT System order from a therapy customer in Finland.
This is a new customer for Nexstim and the system will be used to treat Major Depressive Disorder (MDD).
Nexstim s NBT System with SmartFocus nTMS is highly differentiated from other currently available TMS products due to its unique and highly sophisticated 3D navigation that uses its proprietary E-field algorithm to visualize the exact location, orientation, and magnitude of the stimulation.
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.